DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.

ABSTRACT:

Background

The demethylation agent decitabine (DAC) is a pivotal non-intensive alternative treatment for acute myeloid leukemia (AML). However, patient responses to DAC are highly variable, and predictive biomarkers are warranted. Herein, the DNA methylation landscape of patients treated with a DAC-based combination regimen was compared with that of patients treated with standard chemotherapy to develop a molecular approach for predicting clinical response to DAC.

Methods

Twenty-five non-M3 AML patients were enrolled and subjected to DNA methylation sequencing and profiling to identify differentially methylated regions (DMRs) and genes of interest. Moreover, the effects of a DAC-based regimen on apoptosis and gene expression were explored using Kasumi-1 and K562 cells.

Re

SUBMITTER: He S 

PROVIDER: S-EPMC10830847 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature